Fig. 7: Chronic i.c.v. administration of TLQP-62 peptide ameliorated pathophysiological changes in the 5xFAD mouse brain.
From: Multiscale causal networks identify VGF as a key regulator of Alzheimer’s disease
a Immunohistochemical staining of Aβ amyloid plaques and microglial cells in the male 5xFAD mouse cortex and dentate gyrus after 28-day i.c.v. administration of TLQP-62 peptide or vehicle control (aCSF). Red: Aβ (6E10), green: Iba-1. b Quantification of percent area of Aβ and Iba-1 staining in both peptide-treated male and female 5xFAD mouse brains. Data are presented as mean percentage ± SEM. Results of Aβ(6E10) staining were analyzed by two-sided Student’s t test. Male: cortex, p = 0.0015; DG p = 0.0316; female: cortex, p = 0.0101; CA1, p = 0.022. Iba-1 staining were analyzed by one-way ANOVA with Newman–Keuls post hoc analysis, male cortex: F(2,36) = 8.449, p = 0.001, n = 4, 5, 4 mice per group, 3 slices analyzed per animal; female cortex: F(2,14) = 12.53, p = 0.0008, n = 5, 7, 5 mice per group, *p < 0.05, **p < 0.01, ***p < 0.001. c Reduced staining of Lamp1-immunoreactive dystrophic neurite cluster number in 5xFAD brains after 28-day TLQP-62 i.c.v. infusion. Red: Lamp1, green: 6E10, blue: DAPI. N = 6, 6 male mice per group. Data are presented as mean ± SEM and analyzed by two-sided Student’s t test. *p = 0.024.
